<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806520</url>
  </required_header>
  <id_info>
    <org_study_id>03671-08-C</org_study_id>
    <nct_id>NCT00806520</nct_id>
  </id_info>
  <brief_title>Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control</brief_title>
  <official_title>Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR,&#xD;
      sitagliptin, or pioglitazone. The CGM measurements collected will help determine the&#xD;
      characteristics of glucose control prior to treatment and during treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the Amylin BCB106 Protocol Main Study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  type 2 diabetes&#xD;
&#xD;
          -  A1c 7.1 - 11&#xD;
&#xD;
          -  BMI 25 - 45&#xD;
&#xD;
          -  stable weight for 3 months before screening&#xD;
&#xD;
          -  fasting glucose &lt; 280 at screening&#xD;
&#xD;
          -  stable dose of metformin for at least 2 months before screening&#xD;
&#xD;
          -  not being treated with or on a stable dose of hormone replacement therapy, oral&#xD;
             contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement&#xD;
             therapy, anti-depressants, drugs known to affect body weight&#xD;
&#xD;
          -  male or female, non-lactating, non-pregnant and willing to use birth control&#xD;
&#xD;
          -  lab values that are not clinically significant at screening&#xD;
&#xD;
          -  physical exam and ECG that are not clinically significant at screening&#xD;
&#xD;
          -  able to read, understand, and sign consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  renal disease&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  gastroparesis&#xD;
&#xD;
          -  cancer within 5 years of screening&#xD;
&#xD;
          -  macular edema&#xD;
&#xD;
          -  chronic infections&#xD;
&#xD;
          -  drug or alcohol abuse&#xD;
&#xD;
          -  fasting triglycerides &gt; or = 600 at screening&#xD;
&#xD;
          -  previous exposure to exenatide LAR&#xD;
&#xD;
          -  has donated blood within 60 days of screening or is planning to donate during the&#xD;
             study&#xD;
&#xD;
          -  has had a major surgery or blood transfusion within 2 months before screening&#xD;
&#xD;
          -  is currently being treated or is expecting to be treated with Byetta, Januvia, SU,&#xD;
             TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin,&#xD;
             insulin, systemic corticosteroids, lopid or rifampin&#xD;
&#xD;
          -  has received an investigational drug within 1 month before screening&#xD;
&#xD;
          -  has allergies or hypersensitivity to any component of the study drug&#xD;
&#xD;
          -  has previously had an adverse event related to TZD or Januvia&#xD;
&#xD;
          -  is an immediate family member of the study sight or directly affiliated&#xD;
&#xD;
          -  is employed by Amylin, Lilly or Alkermes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M. Bergenstal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger S. Mazze, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M. Cuddihy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elinor (Ellie) S. Strock, APRN, BS,CDE</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Medical Group</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Diabetes Care Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>Exenatide Once Weekly or</keyword>
  <keyword>Januvia or</keyword>
  <keyword>Actos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

